Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.00223214285714301 -0.0011160714285714 -0.0011160714285714
Stock impact report

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting [Y...

ONO PHARM CO UNSP/ADR (OPHLY) 
NASDAQ:AMEX Investor Relations: ono.co.jp/eng/investor/index.html
Company Research Source: Yahoo! Finance
OSAKA, Japan & WALTHAM, Mass., December 06, 2025 BUSINESS WIRE )--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67 th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. Show less Read more
Impact Snapshot
Event Time:
OPHLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
OPHLY alerts

from News Quantified
Opt-in for
OPHLY alerts

from News Quantified